Atlas Trials

A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis

Clinical trial NCT03952637 · RECRUITING

Trial details

NCT number
NCT03952637
Sponsor
National Human Genome Research Institute (NHGRI)
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Lysosomal DiseasesGangliosidosisGM1
Start date
2019-08-19
Primary completion
2028-01-01
Enrollment
54

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.